Anterior Segment Inflammation
1. Bielory L, Update on ocular allergy treatment, Expert Opin Pharmacother, 2002;3:541–53.
2. McGhee CN, Dean S, Danesh-Meyer H, Locally administered ocular corticosteroids: benefits and risks, Drug Saf, 2002;25:33–55.
3. Stewart R, Horwitz B, Howes J, et al., Double-masked, placebo- controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post- operative Inflammation Study Group 1, J Cataract Refract Surg, 1998;24:1480–9.
4. Forister JF, Forister EF, Yeung KK, et al., Prevalence of contact lens-related complications: UCLA contact lens study, Eye Contact Lens, 2009;35:176–80.
5. Lemp MA, Nichols KK, Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment, Ocul Surf, 2009;7:S1–S14.
6. Gayton JL, Etiology, prevalence, and treatment of dry eye disease, Clin Ophthalmol, 2009;3:405–12.
7. Suttorp-Schulten MS, Rothova A, The possible impact of uveitis in blindness: a literature survey, Br J Ophthalmol, 1996;80:844–8.
8. London NJ, Rathinam SR, Cunningham ET, Jr., The epidemiology of uveitis in developing countries, Int Ophthalmol Clin, 2010;50:1–17.
9. Gritz DC, Wong IG, Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study, Ophthalmology, 2004;111:491–500.
10. Pavesio CE, Decory HH, Treatment of ocular inflammatory conditions with loteprednol etabonate, Br J Ophthalmol, 2008;92:455–9.
11. Jaanus SD, Drug therapy for ocular allergy, Optom Clin, 1992;2:35–44.
12. Congdon NG, Schein OD, von Kulajta P, et al., Corneal complications associated with topical ophthalmic use of nonsteroidal antiinflammatory drugs, J Cataract Refract Surg, 2001;27:622–31.
13. Perry HD, Solomon R, Donnenfeld ED, et al., Evaluation of topical cyclosporine for the treatment of dry eye disease, Arch Ophthalmol, 2008;126:1046–50.
14. O'Brien PD, Collum LM, Dry eye: diagnosis and current treatment strategies, Curr Allergy Asthma Rep, 2004;4:314–9.
15. Owen CG, Shah A, Henshaw K, et al., Topical treatments for seasonal allergic conjunctivitis: systematic review and meta-analysis of efficacy and effectiveness, Br J Gen Pract, 2004;54:451–6.
16. Loteprednol Etabonate US Uveitis Study Group, Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis, Am J Ophthalmol, 1999;537–44
17. Bartlett JD, Horwitz B, Laibovitz R, et al., Intraocular pressure response to loteprednol etabonate in known steroid responders, J Ocul Pharmacol, 1993;9:157–65.
18. Bucala R, Gallati M, Manabe S, et al., Glucocorticoid-lens protein adducts in experimentally induced steroid cataracts, Exp Eye Res, 1985;40:853–63.
19. Manabe S, Bucala R, Cerami A, Nonenzymatic addition of glucocorticoids to lens proteins in steroid-induced cataracts, J Clin Invest, 1984;74:1803–10.
20. Druzgala P, Hochhaus G, Bodor N, Soft drugs--10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate, J Steroid Biochem Mol Biol, 1991;38:149–54.
21. Samudre SS, Lattanzio FA, Jr., Williams PB, et al., Comparison of topical steroids for acute anterior uveitis, J Ocul Pharmacol Ther, 2004;20:533–47.
22. Asbell P, Howes J, A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis, CLAO J, 1997;23:31–6.
23. Dell SJ, Shulman DG, Lowry GM, et al., A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group, Am J Ophthalmol, 1997;123:791–7.
24. Neumann R, Howes JF, Loteprednol etabonate: a novel ocular steroid with improved safety profile. In: Nussenblatt RB, Whitcup SM, Caspi RM, Gery I (eds.), Advances in Ocular Immunology: Proceedings of the 6th International Symposium on the Immunology and Immunopathology of the Eye, New York: Elsevier, 1994;245–8.
25. Novack GD, Howes J, Crockett RS, et al., Change in intraocular pressure during long-term use of loteprednol etabonate, J Glaucoma, 1998;7:266–9.
26. Dell SJ, Lowry GM, Northcutt JA, et al., A randomized, double- masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis, J Allergy Clin Immunol, 1998;102:251–5.
27. Koo EH, Samudre SS, Williams PB, et al., Loteprednol etabonate ophthalmic suspension 0.2% and olopatadine hydrochloride ophthalmic solution 0.1% in the treatment of allergic conjunctivitis, Invest Ophthalmol Vis Sci, 2008;49:Abstract 422.
28. The Loteprednol Etabonate Postoperative Inflammation Study Group 2, A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. The Loteprednol Etabonate Postoperative Inflammation Study Group 2, Ophthalmology, 1998;105(9):1780–6.
29. Bartlett JD, Howes JF, Ghormley NR, et al., Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis, Curr Eye Res, 1993;12:313–21.
30. Friedlaender MH, Howes J, A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I, Am J Ophthalmol, 1997;123:455–64.
31. Pflugfelder SC, Maskin SL, Anderson B, et al., A randomized, double-masked, placebo-controlled, multicenter comparison of
loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance, Am J Ophthalmol, 2004;138:444–57.
32. Sheppard JD, Scoper SV, Samudre S, Topical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye disease, J Ocul Pharmacol Ther, 2011;27(1):23–7.
33. Bartlett JD, Holland EJ, Usner DW, et al., Tolerability of loteprednol/tobramycin versus dexamethasone/tobramycin in healthy volunteers: results of a 4-week, randomized, double-masked, parallel-group study, Curr Med Res Opin, 2008;24:2219–27.
34. Holland EJ, Bartlett JD, Paterno MR, et al., Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers, Cornea, 2008;27:50–5.
35. White EM, Macy JI, Bateman KM, et al., Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis, Curr Med Res Opin, 2008;24:287–96.
36. Panda A, Vanathi M, Kumar A, et al., Corneal graft rejection, Surv Ophthalmol, 2007;52:375–96.
37. Charlin R, Polack FM, The effect of elevated intraocular pressure on the endothelium of corneal grafts, Cornea, 1982;1:241–9.
38. Holland EJ, Djalilian AR, Sanderson JP, Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation, Cornea, 2009;28:1139–43.
39. Mohammadpour M, Jafarinasab MR, Javadi MA, Outcomes of acute postoperative inflammation after cataract surgery, Eur J Ophthalmol, 2007;17:20–8.
40. Henderson BA, Kim JY, Ament CS, et al., Clinical pseudophakic cystoid macular edema. Risk factors for development and duration after treatment, J Cataract Refract Surg, 2007;33:1550–8.
41. Schmier JK, Halpern MT, Covert DW, et al., Evaluation of costs for cystoid macular edema among patients after cataract surgery, Retina, 2007;27:621–8.
42. Comstock TL, Usner DL, Effect of Loteprednol Etabonate Ophthalmic Suspension 0.5% on Post-Operative Pain and Discomfort. Poster presented at the American Society of Cataract and Refractive Surgery Annual Symposium, Boston Massachusetts, April 9–14, 2010.
43. Heier JS, Topping TM, Baumann W, et al., Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema, Ophthalmology, 2000;107:2034–8.
44. Ilyas H, Slonim CB, Braswell GR, et al., Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis, Eye Contact Lens, 2004;30:10–3.
45. Howes J, Novack GD, Failure to detect systemic levels, and effects of loteprednol etabonate and its metabolite, PJ-91, following chronic ocular administration, J Ocul Pharmacol Ther, 1998;14:153–8.
62
US OPHTHALMIC REVIEW
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116